Clément Verkest1,2,3, Emilie Piquet3,4, Sylvie Diochot1,2,3, Mélodie Dauvois1, Michel Lanteri-Minet3,4,5, Eric Lingueglia1,2,3, Anne Baron1,2,3. 1. Université Côte d'Azur, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France. 2. LabEx Ion Channel Science and Therapeutics, Valbonne, France. 3. FHU InovPain, Université Côte d'Azur, Nice, France. 4. CHU Nice, Hopital Cimiez, Département d'évaluation et de traitement de la douleur, Nice, France. 5. Inserm/UdA, U1107, Neuro-Dol, Trigeminal Pain and Migraine, Université d'Auvergne, Clermont-Ferrand, France.
Abstract
BACKGROUND AND PURPOSE: Acid-sensing ion channels (ASICs) are neuronal proton sensors emerging as potential therapeutic targets in pain of the orofacial region. Amiloride, a non-specific ASIC blocker, has been shown to exert beneficial effects in animal models of migraine and in patients. We explored the involvement of the ASIC1-subtype in cutaneous allodynia, a hallmark of migraine affecting cephalic and extra-cephalic regions in about 70% of migrainers. EXPERIMENTAL APPROACH: We investigated the effects of systemic injections of amiloride and mambalgin-1, a specific inhibitor of ASIC1a- and ASIC1b-containing channels, on cephalic and extra-cephalic mechanical sensitivity in a rodent model of acute and chronic migraine induced by i.p. injections of isosorbide dinitrate. KEY RESULTS: I.v. injections of these inhibitors reversed cephalic and extra-cephalic acute cutaneous mechanical allodynia in rats, a single injection inducing a delay in the subsequent establishment of chronic allodynia. Both mambalgin-1 and amiloride also reversed established chronic allodynia. The anti-allodynic effects of mambalgin-1 were not altered in ASIC1a-knockout mice, showing the ASIC1a subtype is not involved in these effects which were comparable to those of the anti-migraine drug sumatriptan and of the preventive drug topiramate on acute and chronic allodynia respectively. A single daily injection of mambalgin-1 also had a significant preventive effect on allodynia chronification. CONCLUSIONS AND IMPLICATIONS: These pharmacological data support the involvement of peripheral ASIC1-containing channels in migraine cutaneous allodynia as well as in its chronification. They highlight the therapeutic potential of ASIC1 inhibitors as both an acute and prophylactic treatment for migraine.
BACKGROUND AND PURPOSE: Acid-sensing ion channels (ASICs) are neuronal proton sensors emerging as potential therapeutic targets in pain of the orofacial region. Amiloride, a non-specific ASIC blocker, has been shown to exert beneficial effects in animal models of migraine and in patients. We explored the involvement of the ASIC1-subtype in cutaneous allodynia, a hallmark of migraine affecting cephalic and extra-cephalic regions in about 70% of migrainers. EXPERIMENTAL APPROACH: We investigated the effects of systemic injections of amiloride and mambalgin-1, a specific inhibitor of ASIC1a- and ASIC1b-containing channels, on cephalic and extra-cephalic mechanical sensitivity in a rodent model of acute and chronic migraine induced by i.p. injections of isosorbide dinitrate. KEY RESULTS: I.v. injections of these inhibitors reversed cephalic and extra-cephalic acute cutaneous mechanical allodynia in rats, a single injection inducing a delay in the subsequent establishment of chronic allodynia. Both mambalgin-1 and amiloride also reversed established chronic allodynia. The anti-allodynic effects of mambalgin-1 were not altered in ASIC1a-knockout mice, showing the ASIC1a subtype is not involved in these effects which were comparable to those of the anti-migraine drug sumatriptan and of the preventive drug topiramate on acute and chronic allodynia respectively. A single daily injection of mambalgin-1 also had a significant preventive effect on allodynia chronification. CONCLUSIONS AND IMPLICATIONS: These pharmacological data support the involvement of peripheral ASIC1-containing channels in migraine cutaneous allodynia as well as in its chronification. They highlight the therapeutic potential of ASIC1 inhibitors as both an acute and prophylactic treatment for migraine.
Authors: Philip R Holland; Simon Akerman; Anna P Andreou; Nazia Karsan; John A Wemmie; Peter J Goadsby Journal: Ann Neurol Date: 2012-10 Impact factor: 10.422
Authors: Hervé Cadiou; Milena Studer; Nicholas G Jones; Ewan St J Smith; Angela Ballard; Stephen B McMahon; Peter A McNaughton Journal: J Neurosci Date: 2007-11-28 Impact factor: 6.167
Authors: Richard B Lipton; Marcelo E Bigal; Sait Ashina; Rami Burstein; Stephen Silberstein; Michael L Reed; Daniel Serrano; Walter F Stewart Journal: Ann Neurol Date: 2008-02 Impact factor: 10.422
Authors: Hannah M Harris; Jessica M Carpenter; Jonathan R Black; Todd A Smitherman; Kenneth J Sufka Journal: J Neurosci Methods Date: 2017-04-23 Impact factor: 2.390
Authors: Simon D Harding; Joanna L Sharman; Elena Faccenda; Chris Southan; Adam J Pawson; Sam Ireland; Alasdair J G Gray; Liam Bruce; Stephen P H Alexander; Stephen Anderton; Clare Bryant; Anthony P Davenport; Christian Doerig; Doriano Fabbro; Francesca Levi-Schaffer; Michael Spedding; Jamie A Davies Journal: Nucleic Acids Res Date: 2018-01-04 Impact factor: 16.971
Authors: E A Bates; T Nikai; K C Brennan; Y-H Fu; A C Charles; A I Basbaum; L J Ptácek; A H Ahn Journal: Cephalalgia Date: 2010-02 Impact factor: 6.292
Authors: Angelo A Izzo; Mauro Teixeira; Steve P H Alexander; Giuseppe Cirino; James R Docherty; Christopher H George; Paul A Insel; Yong Ji; David A Kendall; Reynold A Panattieri; Christopher G Sobey; S Clare Stanford; Barbara Stefanska; Gary Stephens; Amrita Ahluwalia Journal: Br J Pharmacol Date: 2020-04-16 Impact factor: 8.739
Authors: Nina Ruan; Jacob Tribble; Andrew M Peterson; Qian Jiang; John Q Wang; Xiang-Ping Chu Journal: Int J Mol Sci Date: 2021-05-01 Impact factor: 5.923
Authors: Christopher M Holton; Lauren C Strother; Isaac Dripps; Amynah A Pradhan; Peter J Goadsby; Philip R Holland Journal: Br J Pharmacol Date: 2020-03-02 Impact factor: 9.473